IEEE Pulse. 2021 May-Jun;12(3):21-23. doi: 10.1109/MPULS.2021.3078602.
In the wake of the COVID-19 pandemic, the need for rapid and accurate diagnostic testing across populations quickly became evident. In response, the National Institutes of Health (NIH) was determined not only to invest heavily in this area but to change the process by which grant proposals were reviewed and funded in order to spur faster development of viable technologies. The Rapid Acceleration of Diagnostics (RADx) initiative was designed to speed innovation, commercialization, and implementation of potential COVID-19 diagnostic technology. As part of this effort, the RADx Tech initiative focuses on the development, validation, and commercialization of innovative point-of-care, home-based, and clinical lab-based tests that can detect SARS-CoV-2. This effort was enabled through the NIH's National Institute of Biomedical Imaging and Bioengineering (NIBIB) Point-of-Care Technology Research Network (POCTRN).
在 COVID-19 大流行之后,迅速准确地对人群进行诊断测试的需求变得显而易见。有鉴于此,美国国立卫生研究院 (NIH) 不仅决心在这一领域大力投资,而且还改变了审查和资助拨款提案的流程,以促使更快速地开发可行的技术。快速诊断加速 (RADx) 计划旨在加速潜在 COVID-19 诊断技术的创新、商业化和实施。作为这项工作的一部分,RADx Tech 计划侧重于开发、验证和商业化创新的即时护理、家庭和临床实验室测试,可以检测 SARS-CoV-2。这一努力是通过 NIH 的国家生物医学影像与生物工程研究所 (NIBIB) 即时护理技术研究网络 (POCTRN) 实现的。